Recombinant p21 anticorps

N° du produit ABIN6939040

Détail du produit anti-p21 anticorps

Antigène: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp p21 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Specificité: This MAb recognizes a 21kDa protein, identified as the p21WAF1 tumor suppressor protein. This MAb is highly specific to p21 and shows no cross-reaction with other closely related mitotic inhibitors. p21WAF1 is a specific inhibitor of cdk's and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

Réactivité croisée (Details): Human. Does not react with Mouse or Rat,

Purification: 200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G.

Immunogène: Recombinant full-length human CDKN1A protein

Clone: RCIP1-823

Isotype: IgG1

Information d'application

Indications d'application:

Positive Control: HeLa cells. Skin, colon or breast carcinoma.

Known Application: Western Blot (1-2 μg/mL), Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes), Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Stockage

Concentration: 200 μg/mL

Buffer: Prepared in 10 mM PBS with 0.05 % BSA and 0.05 % azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8 °C. Antibody is stable for 24 months. Non-hazardous. Also available WITHOUT BSA & azide at 1.0mg/ml.

Date de péremption: 24 months

Détails sur p21

Antigène: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Autre désignation: CDKN1A (CDKN1A Produits)

Synonymes: anticorps CCND1, anticorps CDKN1A, anticorps CAP20, anticorps CDKN1, anticorps CIP1, anticorps MDA-6, anticorps P21, anticorps SDI1, anticorps WAF1, anticorps p21CIP1, anticorps CDKI, anticorps Cdkn1, anticorps Waf1, anticorps mda6, anticorps p21Cip1, anticorps p21WAF, anticorps Cip1, anticorps UV96, anticorps p21, anticorps cip1, anticorps p16Xic2, anticorps sdi1, anticorps waf1, anticorps cap20, anticorps cdkn1, anticorps mda-6, anticorps p21cip1, anticorps si:ch1073-48m5.2, anticorps KRAS2, anticorps p21ras, anticorps cyclin D1, anticorps cyclin dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A (P21), anticorps cyclin-dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A L homeolog, anticorps cyclin-dependent kinase inhibitor 1, anticorps KRAS proto-oncogene, GTPase, anticorps CCND1, anticorps CDKN1A, anticorps Cdkn1a, anticorps cdkn1a.L, anticorps cki1, anticorps cdkn1a, anticorps KRAS

Sujet: Activating Fragment 1, CAP20, CDK-interacting protein 1, CDKI, CDKN1, CDKN1A, CIP1, Cyclin-dependent kinase inhibitor 1A (p21, Cip1), DNA Synthesis Inhibitor, MDA6, Melanoma Differentiation Associated Protein 6, p21Cip1/Waf1, PIC1, SDI1, SLC12A9, Wild type p53 activated fragment 1 (WAF1),p21WAF1 (Tumor Suppressor Protein)
Cellular localisation: Nuclear

Poids moléculaire: 21kDa

ID gène: 1026, 370771

UniProt: P38936

Pathways: Signalisation p53, Signalisation PI3K-Akt, Cycle Cellulaire, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagy